Pharma BD Deal Intelligence

Pfizer Inc. / FoldRx Pharmaceuticals

2010 · Acquisition/Merger · Complete

Pfizer agreed to acquire privately held FoldRx Pharmaceuticals to gain rare-disease platform anchored by tafamidis, a first-in-class TTR stabilizer. Deal value undisclosed.

Key facts

• Announced Oct 04, 2010
• Deal type Acquisition/Merger
• Therapeutic area Transthyretin amyloid polyneuropathy/cardiomyopathy
• Indications Transthyretin amyloid polyneuropathy/cardiomyopathy
• Key assets Tafamidis (Vyndaqel)
• Mechanism Transthyretin tetramer stabilizer

← Browse all deals  ·  How we score deals